Janux Therapeutics (JANX) vs Olema Oncology (OLMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Janux Therapeutics (JANX) has outperformed Olema Oncology (OLMA) over the past year, losing 65.0% versus a loss of 69.7%. Over five years, JANX leads with a -42.9% price change compared with -66.4% for OLMA. Janux Therapeutics is the larger company by market cap ($616.7 million vs $615.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | OLMA |
|---|---|---|
| Share price | $10.08 | $7.02 |
| Market cap | $616.73M | $615.00M |
| 1-day change | -2.04% | -1.82% |
| YTD return | -26.96% | -71.92% |
| 1-year return | -65.00% | -69.70% |
| 5-year return | -42.92% | -66.36% |
| EPS (TTM) | $-1.59 | $-2.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.00M | — |
| Revenue growth (YoY) | -5.55% | — |
| Net income (latest FY) | $-113.63M | $-162.45M |
| Operating margin | -1576.67% | — |
| Net margin | -1136.25% | — |
| 52-week high | $35.34 | $36.26 |
| 52-week low | $10.05 | $6.24 |
| Distance from 52-week high | -71.48% | -80.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +228.77% | +405.70% |
| Average volume | 961.56K | 1.27M |
| Shares outstanding | 61.18M | 87.61M |
| Employees | 114 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees
About Olema Oncology
OLMA stock →Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
JANX vs OLMA FAQ
Which is bigger, Janux Therapeutics or Olema Oncology?
Janux Therapeutics (JANX) is larger, with a market capitalization of $616.73M compared with $615.00M for Olema Oncology (OLMA).
Which stock has performed better over the past year, JANX or OLMA?
JANX returned -65.00% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Olema Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.